Curis (CRIS) Change in Accured Expenses (2010 - 2026)
Curis' (CRIS) quarterly Change in Accured Expenses came in at $521000.0 in Q1 2026, up 79.66% YoY from $290000.0 in Q1 2025, and down 62.71% on a QoQ basis from $1.4 million in Q4 2025.
Curis (CRIS) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Curis (CRIS) has 17 years of Change in Accured Expenses data on file, last reported at $521000.0 in Q1 2026.
- Quarterly Change in Accured Expenses rose 79.66% year-over-year to $521000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (up 489.6% YoY) and the FY2025 annual result came in at $2.5 million, up 222.58% from the prior year.
- Change in Accured Expenses eased to $521000.0 in Q1 2026, from $1.4 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $4.0 million in Q3 2023 to a low of -$3.9 million in Q1 2022.
- A 5-year average of $26235.3 and a median of $290000.0 in 2025 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2024 — Change in Accured Expenses tumbled 662.39% — and 2025, when it surged 178.31%.
- Tracing CRIS's Change in Accured Expenses over 5 years: stood at -$3.7 million in 2022, then soared by 93.67% to -$234000.0 in 2023, then plunged by 662.39% to -$1.8 million in 2024, then surged by 178.31% to $1.4 million in 2025, then tumbled by 62.71% to $521000.0 in 2026.
- The last three Change in Accured Expenses figures came in at $521000.0 (Q1 2026), $1.4 million (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Curis | 3.27 Mn | -2.35 Mn | - | -832,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 521,000.00 |
| Mar 31, 2026 | 521,000.00 |
| Dec 31, 2025 | 1.40 Mn |
| Dec 31, 2025 | 1.40 Mn |
| Sep 30, 2025 | 1.03 Mn |
| Sep 30, 2025 | 1.03 Mn |
| Jun 30, 2025 | -171,000.00 |
| Jun 30, 2025 | -171,000.00 |
| Mar 31, 2025 | 290,000.00 |
| Mar 31, 2025 | 290,000.00 |
| Dec 31, 2024 | -1.78 Mn |
| Dec 31, 2024 | -1.78 Mn |
| Sep 30, 2024 | 2.78 Mn |
| Sep 30, 2024 | 2.78 Mn |
| Jun 30, 2024 | -816,000.00 |
| Jun 30, 2024 | -816,000.00 |
| Mar 31, 2024 | -2.26 Mn |
| Mar 31, 2024 | -2.26 Mn |
| Dec 31, 2023 | -234,000.00 |
| Dec 31, 2023 | -234,000.00 |